{"id":989235,"date":"2026-08-04T08:37:54","date_gmt":"2026-08-04T12:37:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-reports-second-quarter-2026-financial-results\/"},"modified":"2026-08-04T08:37:54","modified_gmt":"2026-08-04T12:37:54","slug":"exagen-inc-reports-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-reports-second-quarter-2026-financial-results\/","title":{"rendered":"Exagen Inc. Reports Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

\n Achieved record total revenue, test volume and trailing twelve-month ASP<\/em>\n <\/p>\n

\n Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million <\/em>\n <\/p>\n

\n Increased full-year revenue guidance to $72 – $75 million <\/em>\n <\/p>\n

CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\n Three Months Ended June 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Six Months Ended June 30,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Unaudited. In thousands, except
ASP data.<\/em>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Revenue<\/td>\n\u00a0<\/td>\n$<\/td>\n19,941<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n17,202<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n37,247<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n32,700<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n61.3<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n60.4<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n60.2<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n59.7<\/td>\n%<\/td>\n<\/tr>\n
Operating expenses<\/td>\n\u00a0<\/td>\n$<\/td>\n13,939<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n13,025<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n27,558<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n25,513<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(1,722<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(2,630<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(5,136<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(5,995<\/td>\n)<\/td>\n<\/tr>\n
Net loss<\/td>\n\u00a0<\/td>\n$<\/td>\n(3,196<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(4,439<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(7,163<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(8,191<\/td>\n)<\/td>\n<\/tr>\n
Adjusted EBITDA<\/td>\n\u00a0<\/td>\n$<\/td>\n(114<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1,721<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(2,274<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(4,229<\/td>\n)<\/td>\n<\/tr>\n
Trailing-twelve-month average
selling price (ASP)<\/td>\n		\u00a0<\/td>\n$<\/td>\n446<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n428<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n446<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n428<\/td>\n\u00a0<\/td>\n<\/tr>\n
Cash and cash equivalents<\/td>\n\u00a0<\/td>\n$<\/td>\n24,588<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n30,033<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n24,588<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n30,033<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
\n
Second Quarter 2026 and Recent Corporate Highlights: <\/strong>\n <\/p>\n